ライフサイエンスコーパス: bone scan

1 ive or equivocal findings on MRI, CT, and/or bone scan).

2 s on conventional imaging (CT and whole-body bone scanning).

3 hanges in PSA will often antedate changes in bone scan.

4 y on the leukocyte study, as compared to the bone scan.

5 ent a dual-energy X-ray absorptiometry (DXA) bone scan.

6 ocyte studies were also interpreted with the bone scans.

7 itation of metastases from planar whole-body bone scans.

8 s, lymphangiograms, staging laparatomies and bone scans.

9 (PSA), measurable disease, and radionuclide bone scans.

10 number of counts was compared with standard bone scans.

11 ved 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scans.

12 etween standard, CNN-, and gaussian-filtered bone scans.

13 predictive value (NPV), and specificity for bone scans.

14 99m)Tc-methylene diphosphonate ((99m)Tc-MDP) bone scans.

15 n bone metastases as detected by (99m)Tc-MDP bone scans.

16 bone marrow scanning and 99mTc-diphosphonate bone scanning.

17 surveys; five infants also underwent nuclear bone scanning.

18 CTT1057 PET (78.5%) were also detectable on bone scanning.

19 Conventional (99m)Tc-methylene diphosphonate bone scans, (201)Tl tumor imaging, and PET techniques ha

20 t with at least one other conventional scan: bone scanning (24), CT (21), MR (20), (18)F-fluciclovine

21 e rates with (131)I-MIBG scan (64%; P = .1), bone scan (36%; P < .001), and BM histology (34%; P < .0

22 %), and/or appearance of new bone lesions on bone scan (83%).

23 ysis, paired (99m)Tc-methylene diphosphonate bone scans ((99m)Tc-BS) were available for 35 patients a

24 Compared with the standard-of-care bone scanning, (99m)Tc-MIP-1404 and (99m)Tc-MIP-1405 ide

25 hildren: (99m)Tc-methylene diphosphate (MDP) bone scans, (99m)Tc-mercaptoacetyltriglycine (MAG3) reno

26 The purpose of this study was to reveal the bone scan abnormalities in children with leukemia and to

27 e evaluated for the presence of asymptomatic bone scan abnormalities in the lower extremities.

28 ents considered low-volume metastatic by the bone scan actually had localized disease, which is criti

29 mprised 747 men with rising PSA and negative bone scan after surgery (n = 486) or radiation therapy (

30 Within 3 months of diagnosis, 43% had a bone scan and 20% a computed tomography (CT) scan.

31 it possible to perform a dynamic total-body bone scan and a dynamic hepatobiliary scan with time res

32 The remaining two modalities (bone scan and computed tomography [CT]) were used so inf

33 Bone scan and computed tomography scan of the pelvis sho

34 of (18)F-DCFPyL PET/CT or PET/MRI (PET) with bone scan and CT with or without multiparametric MRI (he

35 18)F-DCFPyL) PET after conventional imaging (bone scan and CT with or without multiparametric MRI) he

36 Conventional imaging modalities, including bone scan and CT, are inadequate for identifying sites o

37 detection rate of PSMA PET/CT versus planar bone scan and CT.

38 control compared with conventional imaging (bone scan and either CT or MRI) alone for salvage postpr

39 omography scans of the chest and abdomen and bone scan and have a patent main portal vein and major h

40 steoarthritis are mostly unknown, lesions on bone scan and mechanical malalignment increase risk for

41 PET staging or conventional imaging ((99m)Tc bone scan and pelvic CT or MRI).

42 Twenty-eight patients who received both bone scan and plasma fluoride measurements for skeletal

43 PDB had positive diagnostic findings on the bone scan and subsequent radiograph imaging.

44 d a negative result at conventional imaging (bone scan and/or CT).

45 Radionuclide bone scanning and CT supplement clinical and biochemical

46 ly replace other staging procedures, such as bone scanning and possibly contrast-enhanced CT of the t

47 In 32 patients, bone scanning and PSMA PET were performed before therapy

48 In 31 patients, bone scanning and radiologic imaging were performed for

49 Bone scans and anthropometric and dietary assessments we

50 Bone scans and brain imaging were not obtained in 34% an

51 f beneficiaries with breast cancer underwent bone scans and half of beneficiaries with lung cancer or

52 s with prostate cancer, who were imaged with bone scans and PSMA PET performed within 100 d, were inc

53 Early and delayed whole-body bone scans and radiographs were reviewed retrospectively

54 ent baseline conventional imaging (CT/MRI or bone scan) and PET/CT.

55 ce imaging [MRI], selective angiography, and bone scanning) and somatostatin receptor scintigraphy do

56 ing (abdominopelvic contrast-enhanced CT and bone scanning) and the other receiving conventional imag

57 rcent to 76% of women had a mammogram, 24% a bone scan, and 14% a CT scan in the 0-18 and 18-36 month

58 Radiographic, bone scan, and CT severity were not related to time to h

59 Conventional imaging ((18)F-FDG PET/CT, bone scan, and diagnostic CT) was required within 3 wk o

60 maging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [M

61 ividual comparison group, workup by CT, MRI, bone scanning, and (68)Ga-PSMA-11 PET resulted in a posi

62 of the other 4 modalities (CT, MRI [n = 1], bone scanning, and (68)Ga-PSMA-11 PET) was recorded as f

63 t fracture, diagnostic performance of CT and bone scanning, and strength of evidence (SOE) were asses

64 e lesions, improvement in PFS, resolution of bone scans, and reductions in bone turnover markers, pai

65 Group Criteria 3 (using PSMA PET instead of bone scan), aPERCIST, and PSMA PET progression (PPP) cri

66 Bone marrow aspirate and biopsy and bone scan are unnecessary in at least one third of patie

67 Bone scans are reported as "new lesions" or "no new lesi

68 There were 25 subjects who underwent bone scans at both time points (baseline and week 12) an

69 Similarly, patients with positive bone scans at diagnosis had worse EFS than those with ne

70 sive disease, and five did not have a repeat bone scan because of PSA progression.

71 Patients with available bone scans before treatment with (223)Ra and at treatmen

72 r MRI, and a (99m)Tc-methylene diphosphonate bone scan) before enrollment.

73 nts at initial staging, with 57% of positive bone scans being false positives.

74 Two ADPCa patients had positive bone scans; both improved.

75 Physicians often order periodic bone scans (BS) to check for metastases in patients with

76 ed on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria.

77 For women with only an abnormal bone scan but without bony destruction by imaging studie

78 MIBG scans showed more skeletal lesions than bone scans, but the normally high physiologic brain upta

79 cedures decreased by 45%, lung scans by 56%, bone scans by 60%, myocardial studies by 66%, and thyroi

80 However, the accuracy of bone scanning can be improved with the addition of SPECT

81 uted tomography, magnetic resonance imaging, bone scanning, cardiovascular nuclear imaging, nonobstet

82 improved understanding of treatment-induced bone scan changes.

83 nt metastases were diagnosed by radionuclide bone scan, chest radiograph, or other body imaging, whic

84 of a conventional staging approach including bone scanning, chest radiography, or dedicated CT and ab

85 Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts,

86 The use of CBCs, chemistry panels, bone scans, chest radiographs, liver ultrasounds, comput

87 of complete blood counts, chemistry panels, bone scans, chest radiographs, liver ultrasounds, pelvic

88 ine-131 metaiodobenzylguanidine (MIBG) scan, bone scan, computed tomography (and/or magnetic resonanc

89 Diagnostic applications such as the bone scan continue to be the most common use in oncology

90 imaging studies-including chest radiography; bone scanning; contrast material-enhanced computed tomog

91 to 5 subgroups, each containing 10 simulated bone scans, corresponding to BSI values of 0.5, 1.0, 3.0

92 deoxyglucose PET-CT or conventional staging (bone scan, CT of the chest/abdomen and pelvis).

93 retation of the PET images was compared with bone scan, CT, and clinical follow-up findings.

94 , and with at least one metastatic lesion on bone scan, CT, or MRI.

95 tate and metastatic disease as documented by bone scans, CT scans, or MRI scans, and radiographic or

96 as a reflex test if computed tomography plus bone scan (CTBS) was negative or equivocal (CTBS + PSMA-

97 onventional imaging (computed tomography and bone scan [CTBS]) followed by PSMA-PET if CTBS findings

98 A subsequent bone scan demonstrated evolution of the vascular comprom

99 The bone scan did not reveal evidence of osteomyelitis.

100 Overall, we show that technetium-99m bone scans done at regular intervals are a sensitive scr

101 e micro-CT datasets comprising a total of 40 bone scans, each annotated by three experts to assess in

102 Scan Index, is based on an inspection of the bone scan, estimating visually the fraction of each bone

103 ed tomography/magnetic resonance imaging and bone scan) evaluated patients with newly diagnosed metas

104 onal imaging modalities such as MRI, CT, and bone scan findings, but advanced molecular imaging techn

105 /pelvis scans, three limited MRI scans, four bone scans, five gallium scans, two laparotomies and one

106 agreement for bone disease was moderate for bone scans (Fleiss kappa, 0.51) and substantial for the

107 d the following features at the time of each bone scan for association with a positive BS: preoperati

108 ntrast material enhancement and radionuclide bone scanning for detection of brain or skeletal metasta

109 MR imaging was no more accurate than bone scanning for skeletal evaluation.

110 index (aBSI) as a quantitative assessment of bone scans for radiographic response in patients with me

111 A bone scan from an outside hospital was reviewed, and fur

112 thods: In a multicenter retrospective study, bone scans from patients with mCRPC treated with monthly

113 The mouse bone scan had improved image resolution using the PET in

114 Bone scan had significantly lower specificity and sensit

115 Although planar bone scanning has recognized limitations, in particular,

116 Traditional skeletal survey and bone scans have sensitivity limitations for osteolytic l

117 Good correlation was seen with bone scanning; however, more lesions were demonstrated w

118 Results: Bone scan images at baseline were available from 156 pat

119 etraacetic acid ((51)Cr-EDTA) and whole-body bone scan images were acquired at 10 min, 1, 2, 3, and 4

120 different sets of training images: simulated bone scan images, images of a cylindric phantom with hot

121 best standard filters, for the cylindric and bone scan images, respectively.

122 images of a cylindric phantom and simulated bone scan images.

123 We examined baseline and 12-wk bone scan images.

124 When interpreted with bone scans, images obtained in the antibody and (111)In-

125 We performed bone scan imaging in twelve patients (6 females, 6 males

126 we describe the importance of the whole-body bone scan in diagnosing the multifocality of chronic rec

127 correctly positive in seven, SRS in six, and bone scan in five.

128 termine the diagnostic performance of CT and bone scanning in the detection of occult fractures by us

129 nning may enhance the diagnostic accuracy of bone scanning in the evaluation of children with skeleta

130 ling longitudinal bone accrual across 11,000 bone scans in a cohort of healthy children and adolescen

131 to gain insight about the effects of TKIs on bone scans in prostate cancer, we systematically evaluat

132 on MR images in four of five patients and on bone scans in three of five patients.

133 d 153Sm indicate a reduction of hot spots on bone scans in up to 70% of patients, and suggest a possi

134 Guidelines for the use of bone scanning (in patients with PSA level > 10 ng/mL) an

135 68% of evaluable patients had improvement on bone scan, including complete resolution in 12%.

136 e of this study was to evaluate an automated bone scan index (aBSI) as a quantitative assessment of b

137 umor burden was estimated with the automated bone scan index (aBSI, EXINI v2.0) on BS and with the WB

138 ffusion volume (tDV) was correlated with the bone scan index (BSI) and other prognostic factors by us

139 to evaluate the performance of the automated bone scan index (BSI) as an imaging biomarker in patient

140 The bone scan index (BSI) is a promising candidate, being a

141 e prostate-specific antigen blood value, the bone scan index (BSI), and disease classification using

142 skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients who have advanced met

143 quantify metastatic bone lesions, called the Bone Scan Index, is based on an inspection of the bone s

144 asurement of fluoride may be considered when bone scan is not readily available.

145 Use of alendronate before bone scanning is unlikely to result in decreased detecti

146 ourse, including surgical interventions, and bone scans is described.

147 Skeletal scintigraphy (bone scan) is very sensitive in the detection of osseous

148 an response, defined as >/= 30% reduction in bone scan lesion area.

149 on magnetic resonance imaging correspond to bone scan lesions.

150 While use of radiographs and bone scan may be important to rule out other entities, M

151 Single- or multiphasic bone scans may localize common soft-tissue tumors in neu

152 h a baseline and a treatment discontinuation bone scan (median, 5 doses; interquartile range, 3-6 dos

153 efining disease status requires CT (or MRI), bone scan, metaiodobenzylguanidine (MIBG) scan, bone mar

154 Nuclear imaging techniques such as bone scans, metaiodobenzylguanidine (MIBG) scans, and (1

155 is of leukemia was suggested on the basis of bone scans obtained as part of the initial work-up for u

156 he medical records and two-phase, whole-body bone scans of 14 patients (mean age 10.5 yr) with the di

157 y-phase knee scans and late-phase whole-body bone scans of 15 additional joint sites were scored semi

158 hanges (kappa = 0.70, P < 0.0001) was in the bone scans of 173 patients.

159 The mean BSI difference between the 2 repeat bone scans of 35 patients was 0.05 (SD = 0.15), with an

160 Follow-up bone scan study: 2 follow-up bone scans of metastatic prostate cancer patients were a

161 of standardizing quantitative changes in the bone scans of patients with metastatic prostate cancer.

162 to standardize the evaluation of changes in bone scans of prostate cancer patients with skeletal met

163 hus highlight the importance of performing a bone scan or PET CT in cases of carcinoma of the gall bl

164 stopathology, presence on correlative CT/MRI/bone scan or PSA response after focal therapy.

165 ng/mL, and had undergone CI-that is, CT plus bone scanning or whole-body MRI.

166 iagnostic tests, mostly CT (n = 43, 29%) and bone scans or (18)F-NaF PET (n = 52, 35%), were prevente

167 or follow-up confirmatory imaging (CT, MRI, bone scan, or (18)F-fluciclovine PET/CT) as the SoT.

168 aphy (CT), magnetic resonance imaging (MRI), bone scan, or other imaging modalities.

169 of >=8, presence of three or more lesions on bone scan, or presence of measurable visceral metastasis

170 stopathology, presence on correlative CT/MRI/bone scanning, or PSA response after focal therapy.

171 Cabozantinib resulted in improvements in bone scans, pain, analgesic use, measurable soft tissue

172 Within that group of 25, we found 5 bone scan partial responses and 1 complete response.

173 Conclusion: Quantitative SPECT/CT of bone scans performed at baseline is prognostic for survi

174 Bone scan plus CT can continue to serve as a cost-effect

175 PSMA PET/CT and bone scan plus CT detected an equal number of bone lesio

176 ore bone lesions for six patients (27%), and bone scan plus CT detected more bone lesions for two pat

177 DT, 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT had identical bone metastasis detectio

178 er-reader agreement rates of PSMA PET/CT and bone scan plus CT were 96% and 82%, respectively (p = 0.

179 as not been prospectively compared to planar bone scan plus CT.

180 defined as >/= two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory

181 anning via either conventional imaging only (bone scanning plus abdominopelvic CT or MRI) (arm A) or

182 Group A patients with bone scans positive for facet joint abnormalities receiv

183 )In-labeled leukocyte study, the three-phase bone scanning procedure, and dual-tracer studies.

184 malignant breast lesions on sestamibi scans, bone scans, radioiodine studies, as well as PET studies

185 PET is used as the gatekeeper in addition to bone scanning, radionuclide therapy with (223)Ra may be

186 PET is used as the gatekeeper in addition to bone scanning, radionuclide therapy with (223)Ra may be

187 competitive interference with 99mTc-labeled bone scanning reagents.

188 Bone scan response (BSR) at week 12 as assessed by indep

189 hese outcomes were observed in both cohorts: bone scan response in 73% and 45%, respectively; reducti

190 found a relatively high rate of (99m)Tc-MDP bone scan response to sunitinib among men with metastati

191 The primary end point was bone scan response, defined as >/= 30% reduction in bone

192 Ninety-one patients (63%) had a bone scan response, often by week 6.

193 to define the incidence of at least partial bone scan response.

194 e found that none of the subjects exhibiting bone scan responses experienced concordant improvements

195 A nomogram for predicting the bone scan result was constructed with an overfit-correct

196 ine physician, who had full knowledge of the bone scan results.

197 the correlation between plasma fluoride and bone scan results.

198 negative findings at conventional CT and/or bone scanning (sample 2) were enrolled between January a

199 ated most strongly with the early-phase knee bone scan scores (P = 0.0003), even after adjustment for

200 for OA severity according to the late-phase bone scan scores (P = 0.015), as well as synovial fluid

201 m COMP levels correlated with the total-body bone scan scores (r = 0.188, P = 0.018) and with a facto

202 There was no correlation between bone scan scores and outcome following induction therapy

203 P = 0.018) and with a factor composed of the bone scan scores in the shoulders, spine, lateral knees,

204 modeling was used in the correlation of the bone scan scores with the COMP levels.

205 A bone scan showed diffuse bony involvement including the

206 Simulation study: bone scan simulations with predefined tumor burdens were

207 Follow-up bone scan study: 2 follow-up bone scans of metastatic pr

208 Repeat bone scan study: to assess the reproducibility in a rout

209 regression, and improvement on radionuclide bone scans than did patients with androgen-independent p

210 and protein C deficiency was referred for a bone scan to rule out osteomyelitis of the right tibia.

211 tivity and specificity, are recommended over bone scanning to screen for bone metastases in patients

212 erefore, we aimed to evaluate the ability of bone scans to detect osseous metastases using PSMA PET a

213 (PSMA) PET has a higher accuracy than CT and bone scans to stage patients with prostate cancer.

214 s, women seeing medical oncologists had more bone scans, tumor antigen testing, chest x-rays, and che

215 We measured bone scans, tumor antigen tests, chest x-rays, and other

216 Of 25 patients with positive bone scans, two had improvement, seven had stable diseas

217 tigraphic response was evaluated by MIBG and bone scans using a semi-quantitative scoring system.

218 d whether noise can be removed in whole-body bone scans using convolutional neural networks (CNNs) tr

219 The number of lesions detected by bone scan varied from 1-18 (mean 6).

220 diagnosing bone lesions was 89.7% for planar bone scanning versus 98.3% for (18)F-FDG PET/CT.

221 Increased tracer uptake on bone scan was considered positive for periostitis.

222 Bone scan was positive in 52 patients, MRI in seven, and

223 Bone scan was routine through 2002.

224 Radiographic progression on CT or bone scanning was observed within 3 mo of progression on

225 99mTc-methylene diphosphonate (MDP) bone scanning was performed before they received alendro

226 Quantitative whole-body bone scanning was performed, and radioactivity deposited

227 multicenter retrospective study, the PPV of bone scans was low in patients at initial staging, with

228 87 y) attending our department for a routine bone scan were injected with 600 MBq (99m)Tc-MDP, and 4

229 Alkaline phosphatase and technetium bone scan were sensitive ways of detecting early disease

230 osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30

231 results of the monoclonal antibody study and bone scanning were more accurate (0.91) for diagnosing t

232 -11 and (18)F-FDG PET/CT, diagnostic CT, and bone scanning were performed at study entry and exit.

233 l staging, the PPV, NPV, and specificity for bone scans were 0.43 (95% CI, 0.26-0.63), 0.94 (95% CI,

234 patients, the PPV, NPV, and specificity for bone scans were 0.73 (95% CI, 0.61-0.82), 0.82 (95% CI,

235 Bone scans were evaluated for geographic and anatomic lo

236 Bone scans were interpreted as positive for osteomyeliti

237 iphase (99m)Tc-hydroxyethylene diphosphonate bone scans were negative early, but late-phase (>3 h) up

238 efinitive therapy for localized disease, (b) bone scans were negative, and (c) anti-3-(18)F-FACBC pos

239 Bone scans were obtained by pQCT from the distal epiphys

240 lity in a routine clinical setting, 2 repeat bone scans were obtained from metastatic prostate cancer

241 (99m)Tc-hydroxymethylene diphosphonate bone scans were only positive at day 14 in RA versus sha

242 ultiphase 99mTc methylenediphosphonate (MDP) bone scans were performed in five patients with neurofib

243 Baseline radionuclide bone scans were reviewed in 191 assessable patients with

244 Fifty bone scans were simulated with a tumor burden ranging fr

245 The best CNNs for the cylindric phantom and bone scans were the dedicated CNNs.

246 onventional imaging (negative CT or MRI, and bone scan) were eligible.

247 , magnetic resonance image, angiography, and bone scan) were performed, and the management was propos

248 egion demonstrating abnormal activity on the bone scan, which was more intense than adjacent marrow a

249 ive prostate adenocarcinoma evident on CT or bone scanning with (99(m))Tc and an Eastern Cooperative

250 Dynamic bone scanning with (99m)Tc-labeled diphosphonates and (1

251 ct metastases for CNN- and gaussian-filtered bone scans with half the number of counts was compared w

252 CT and bone scanning yielded comparable diagnostic performance